Ractigen - Ractigen Therapeutics

Company News News Highlight RAG-01

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

Nantong, China – March 19, 2026 – Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small…

RactigenMarch 19, 2026

Company News Homepage News News Highlight RAG-17 Uncategorized

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…

RactigenJanuary 13, 2026

Homepage News News Highlight

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, December 12, 2025 – Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA)…

RactigenDecember 12, 2025

Homepage News News Highlight

Ractigen Publishes Foundational Paper Detailing Its SCAD Platform for Duplex RNA Delivery to the CNS and Beyond in Molecular Therapy – Nucleic Acids

SUZHOU, China, November 17, 2025 – Ractigen Therapeutics, a clinical-stage biotechnology company, today announced the publication…

RactigenNovember 17, 2025